The burden-of-illness study on osteoporosis in the Slovenian female population
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
This burden-of-illness study on osteoporosis was performed with the main goal to estimate the economic implications of osteoporosis for the Slovenian healthcare system.
A variety of sources was used to quantify the utilization of resources in 2003, and the appropriate unit costs were assigned to the identified resources.
Main outcome measures
The study included all direct and indirect costs that arise from treatment of osteoporosis and consequent hip, spine and wrist fractures in total Slovene postmenopausal population in 2003.
We estimated the total burden of postmenopausal osteoporosis in Slovenia for 2003 to be over SIT 7.55 billion (approximately €31.5 million); among that, 45% or SIT 3.39 billion (€14.2 million) belong to drug expenditures for osteoporosis treatment and prevention; 29% or SIT 2.2 billion (€9.2 million) include indirect costs for osteoporosis morbidity and mortality, and 26% or SIT 1.95 billion (€8.1 million) belong to direct costs for treatment, hospitalization, and rehabilitation of osteoporotic fractures. Total costs on osteoporotic fractures were however subject to an approximation due to the expert panel-based estimate of proportion of osteoporosis-caused fractures and the limited data on resource utilization for fracture treatment.
Osteoporosis is a costly disease with a significant burden to society and needs to be viewed as an important problem with a complex long-term impact.
- WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994) World Health Organization Technical Report Series 843:5–6
- Sedrine W, Radican L, Reginster J-Y On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center. Rheumatology 2001;40:7–14 CrossRef
- Morrison A, Wertheimer AI Types of Pharmacoeconomic Evaluation. In: Morrison A, Wertheimer AI, editors. Pharmacoeconomics. A primer for the pharmaceutical industry. Philadelphia: Temple University; 2002
- National Osteoporosis Foundation Status Report. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis International 1998; 8(S4):S1–S88
- Ray N, Chan J, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997;12(1):24–35 CrossRef
- Max W, Sinnot P, Kao C et al. The burden of osteoporosis in California, 1998. Osteoporosis International 2002;13:493–500 CrossRef
- Dolan P, Torgerson DJ The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis International 1998;8:611–617 CrossRef
- Lane A Direct costs of osteoporosis for New Zealand women. PharmacoEconomics 1996;9(3):231–245
- Rosner A, Grima D, Torrance G et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14(5):559–573 CrossRef
- IVZ. Ambulantno predpisovanje zdravil v Sloveniji po ATC klasifikaciji v letu; 2003. Available via <http://www.ivz.si>
- Inštitut za varovanje zdravja Republike Slovenije: Zdravstveni statistični letopis; 2003
- Melton III L, Thamer M, Ray N et al. Fractures attributable to osteoporosis: report from the national osteoporosis foundation. Journal of Bone and Mineral Research 1997;12(1):16–23 CrossRef
- Ferk J Osteoporotični zlomi kolka, zapestja in hrbteničnega vretenca ter stroški zdravljenja Zdravniški Vestnik 2002;71:41–44
- Koopmanschap AM, Rutten FH A practical guide for calculating indirect costs of disease. PharmacoEconomics 1996;10(5):460–466 CrossRef
- De Laet C, Van Hout B, Burger H et al Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam study. Osteoporosis International 1999;10(1):66–72 CrossRef
- Vestergaard P, Rejnmark L, Mosekilde L Hip fracture prevention. Cost-effective strategies. Pharmacoeconomics 2001;19(5Pt1):449–468 CrossRef
- Kanis J, Oden A, Johnell O et al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International 2001;12:417–427 CrossRef
- Ankjaer-Jensen A, Johnell O Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis International 1996;6:265–275 CrossRef
- The burden-of-illness study on osteoporosis in the Slovenian female population
Pharmacy World & Science
Volume 29, Issue 4 , pp 404-411
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Bone fractures
- Health policy
- Industry Sectors
- Author Affiliations
- 1. Millennium Pharmaceuticals, Ltd., Building 3, Chiswick Park, 566 Chiswick High Road, London, W4 5YA, UK
- 2. Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, Askerceva 7, 1000, Ljubljana, Slovenia
- 3. Center for Pharmaceutical Health Services Research, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA, 19140, USA